[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@dg_fit61882](/creator/twitter/dg_fit61882) "$RMD chatter picking up rumors of a partnership or even buyout of $IXHL are circulating. It might not be just smoke. Dr. Alison Wimms a ResMed rep officially sits on IXHLs clinical advisory board for their sleep apnea program. Thats not speculation thats real. If IXHLs non-CPAP pill works it could disrupt RMDs core market. Getting in early could be strategic. But its still early-stage. No deals been announced and IXHLs data is still pending. Could be positioning. Could be just pumpers. Either way watching closely $IXHL $RMD #biotech #sleepapnea"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949209373722763421) 2025-07-26 20:45:03 UTC XXX followers, 1096 engagements "$LRMR will report OLE data in Sept for nomlabofusp in Friedreichs Ataxia. Key: confirm skin FXN as surrogate for BLA in Q2 2026. Prior Ph2 showed 3.54.2x increase in FXN vs baseline. If OLE data confirms path to approval shortens. $157M cash. Single-asset risk remains"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1944504592668238004) 2025-07-13 21:09:56 UTC XXX followers, XXX engagements "7/12 Cash runway ✔ They ended Q1 2025 with $12.7M and raised another $5M in April. That covers pre-launch operations into early 2026 based on recent filings. No debt. Low burn. Theyre lean and laser-focused on launch"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1948104188657058158) 2025-07-23 19:33:27 UTC XXX followers, XXX engagements "Bright Minds Biosciences $DRUG trades at $XXXXX giving it a market cap of $250M with just 7.08M shares outstanding (7375% institutional ownership) . Its lead molecule BMB101 is now in an open-label Phase X trial for absence epilepsy & DEE after XXX% seizure survival in SUDEP mouse models . TD Cowen and Chardan initiated Buy coverage with price targets in the $80$92 range . Highly selective 5HT2C agonist designed to minimize tolerance via Gq pathway activation. Phase X depends on upcoming data. #Biotech #Epilepsy #CNS #Microcap"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949196238639026450) 2025-07-26 19:52:52 UTC XXX followers, XX engagements "🚨 $CMG New position opened after earnings: CMG 10/17 XXXX C @ XXXX avg ✳ Q2 2025 Earnings Recap 🔹 Revenue: $3.06B (+3% YoY) 🔹 Same-store sales: X% (first decline since 2020) 🔹 EPS: $XXXX (in line) 🔹 Net income: $436M 🔹 Digital sales: XXXX% of total 🔹 Buybacks: $435.9M repurchased ($50/share); $838.8M still authorized ✳ Valuation (as of July XX 2025) 🔹 Market Cap: $62.7B 🔹 EV/EBITDA: XXXX 🔹 P/E (TTM): XX down XX% from 12mo avg (50) 🔹 Forward P/E: XX ✳ Outlook 🔹 FY25 guide: flat comp sales (cut from low-single digit growth) 🔹 Plan to open 315345 new units (80% with Chipotlanes) 🔹"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949223867421184345) 2025-07-26 21:42:39 UTC XXX followers, XXX engagements "🔬 Q3 2025 Phase X Readouts $LLY Donanemab (Alzheimers Disease) Eli Lillys anti-amyloid antibody is a front-runner in the Alzheimers race. Prior results showed cognitive slowing in early AD but safety concerns over ARIA remain under scrutiny. Q3 data could solidify approval odds. $ATAI GRX-055 (Intranasal 5-MeO-DMT for TRD). A fast-acting psychedelic analog designed for treatment-resistant depression. ATAI is testing whether a short psychedelic experience (via 5-MeO-DMT) can provide rapid symptom relief. A successful readout would validate a novel CNS delivery mechanism. $GBIO GB-501 (Gene"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949586214014812230) 2025-07-27 21:42:29 UTC XXX followers, XXX engagements "$PASG up XX% over that $X i was looking for. Took full position. See previous tweets"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1948739205947162738) 2025-07-25 13:36:47 UTC XXX followers, XXX engagements "$VKTX just kicked off Phase X VANQUISH trials (VANQUISH1 & 2) for its GLP1/GIP dual agonist VK2735 with 6600 patients across 78-week arms testing doses of XXX XXXX & XXXX mg vs placebotargeting obese adults with/without T2D. Primary endpoint: % weight loss vs placebo at XX weeks . Meanwhile the VENTUREOral Phase X trial (280 patients) wrapped enrollment in Q1 and expects topline results in 2H 2025 featuring percent bodyweight change at XX weeks safety PK and dose response across multiple tablet doses . Why it matters: Strong oral data (8.2% mean loss in XX days) could validate VK2735 as an"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949610602877587838) 2025-07-27 23:19:24 UTC XXX followers, XXX engagements "$NVNI jumped nearly XX% at open after its NuviniAI day in So Paulo and unveiling its Latin American SaaS/AI strategy. They presented strong 2024 financials and outlined an M&A pipeline worth $127M targeting closing in Q3"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949827808793887231) 2025-07-28 13:42:30 UTC XXX followers, XX engagements "The biotech space is on fire. Which of these are you watching $SRPT $IXHL $ABVX $RPRX $CRSP $DNA Safety drama breakout charts big trials and buy signals Which ones on your radar and why Drop your take 👇 #Biotech #Stocks #Momentum"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949118174043275353) 2025-07-26 14:42:40 UTC XXX followers, XXX engagements "$SLRX surged over XXX% today after executing a 1-for-8 reverse stock split consolidating the cap and clearing Nasdaq bid-price issues. The company also received a fresh extensionuntil midAugustto regain compliance with the $2.5M equity standard. A third merger amendment with Decoy Therapeutics allows certain creditors to convert debt into Series B preferred stock. Legacy holders retain XXX% post-merger"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1950183285772210606) 2025-07-29 13:15:02 UTC XXX followers, XX engagements "$PASG resistance @ XXX XXX XXXX XXX. Data soon"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1948763758400291204) 2025-07-25 15:14:20 UTC XXX followers, XX engagements "$PASG just saw insider buying from XX% holder Lynx1 Capital128848 shares scooped in the $5.40$5.70 range ($720K). This lines up perfectly with the potential double bottom setup near $XXXX. Big money stepping in right where the chart needed it 👀 data soon"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1948565051939705301) 2025-07-25 02:04:45 UTC XXX followers, XXX engagements "Adaptimmune $ADAP has agreed to sell its TECELRA letecel afamicel and uzacel Tcell therapy programs to US WorldMeds for $55M upfront + up to $30M in milestones closing this week. Post-close ADAP plans to reduce its workforce by XX% and exit leadership roles soon. The company will pivot to development of its PRAME- and CD70-directed programs. ##ADAP #CellTherapy #Biotech"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949842043238531243) 2025-07-28 14:39:04 UTC XXX followers, XXX engagements "$PASG Double Bottom If we pop with some volume ill take a position. Last reported cash 63mil. Market cap 16mil. Couple of catalysts this year. Anyone watching"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1947492145579102671) 2025-07-22 03:01:24 UTC XXX followers, XXX engagements "@PeloSwing $LCID finally showing some life after months of tight range compression. This kind of move off the lows can catch shorts offside. Lets see if it can hold over $3"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949171889194078711) 2025-07-26 18:16:06 UTC XXX followers, XXX engagements "🚨 Big news: U.S. and EU strike a landmark trade deal U.S. to impose a XX% tariff on most EU goods in exchange for $XXX B in investments and $XXX B in energy & defense purchases from Europe Markets are rallying: all-time highs across $SPX $DJI $NDX and European equities like $SX5E (Euro Stoxx50) are gaining reducing downside risk and providing a welcome lift post-uncertainty. Investors view this as a stabilizing catalyst amid upcoming earnings and policy events. 💹 #trade #tariffs #marketrally"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949542875953586604) 2025-07-27 18:50:17 UTC XXX followers, XX engagements "8/ 🔭 Catalysts Still Coming Even in a tough tape 2H 2025 brings big moments: $PMN Phase 1b readout $IXHL Phase X data next week $ABVX launching Phase X UC $VYGR tau program advancing $ACAD mid-stage psychosis data Eyes on timelines"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949291900651081865) 2025-07-27 02:12:59 UTC XXX followers, XXX engagements "$PASG just took a starter. Will wait for volume to come in for a larger allocation"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1947671467648233589) 2025-07-22 14:53:58 UTC XXX followers, XXX engagements "UnitedHealth $UNH July XX 2025 update: CEO shift in May: Stephen Hemsley returns after Andrew Witty steps down Q1 miss triggered withdrawal of 2025 forecast; guidance suspended DOJ has launched civil & criminal probes into MA billing practices Stock down 4045% in 2025; analysts maintain moderate buy consensus Forward P/E at 1415 roughly XX% below long-term average Outlook: focused on cost control in Medicare Advantage and turning Optum performance around Still massive scale & cash flow but visibility remains weak until Q2 numbers. #Healthcare #Insurance #UNH"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949653587300348310) 2025-07-28 02:10:12 UTC XXX followers, XXX engagements "@PeloSwing Bought some long term $CMG XXXX calls"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949213695470715033) 2025-07-26 21:02:14 UTC XXX followers, XX engagements "9/ 🧵 XX Stocks to Watch Across the Sector Heres a mix of leaders innovators and speculative names: $LLY $RHHBY $CRSP $EDIT $BEAM $VYGR $ACAD $PMN $ABVX $IXHL $REGN $BIIB $MGNX $CELA $NVAX $SPRO $XOMA $GNFT $VRTX $ICON Tag your favorites"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949291903020589482) 2025-07-27 02:13:00 UTC XXX followers, XXX engagements "$PASG 3x average volume up 8%. Will look for continuation over $X for a full entry"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1947748804859727916) 2025-07-22 20:01:17 UTC XXX followers, XX engagements "$DMAC is on deck for a pivotal readout: preliminary safety BP & placental flow data from Phase X Part 1A preeclampsia study are expected midJuly. With no approved treatments and $37M cash to Q3 2026 this could mark a breakthroughor highlight early safety/efficacy risks"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1944471934521184484) 2025-07-13 19:00:10 UTC XXX followers, XXX engagements "🚨 U.S. and EU strike a landmark trade deal U.S. to impose a XX% tariff on most EU goods in exchange for $XXX B in investments and $XXX B in energy & defense purchases from Europe Markets are rallying: all-time highs across $SPX $DJI $NDX and European equities like $SX5E (Euro Stoxx50) are gaining reducing downside risk and providing a welcome lift post-uncertainty. Investors view this as a stabilizing catalyst amid upcoming earnings and policy events. 💹 #trade #tariffs #marketrally"  [@dg_fit61882](/creator/x/dg_fit61882) on [X](/post/tweet/1949552547318190127) 2025-07-27 19:28:42 UTC XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@dg_fit61882
"$RMD chatter picking up rumors of a partnership or even buyout of $IXHL are circulating. It might not be just smoke. Dr. Alison Wimms a ResMed rep officially sits on IXHLs clinical advisory board for their sleep apnea program. Thats not speculation thats real. If IXHLs non-CPAP pill works it could disrupt RMDs core market. Getting in early could be strategic. But its still early-stage. No deals been announced and IXHLs data is still pending. Could be positioning. Could be just pumpers. Either way watching closely $IXHL $RMD #biotech #sleepapnea"
@dg_fit61882 on X 2025-07-26 20:45:03 UTC XXX followers, 1096 engagements
"$LRMR will report OLE data in Sept for nomlabofusp in Friedreichs Ataxia. Key: confirm skin FXN as surrogate for BLA in Q2 2026. Prior Ph2 showed 3.54.2x increase in FXN vs baseline. If OLE data confirms path to approval shortens. $157M cash. Single-asset risk remains" @dg_fit61882 on X 2025-07-13 21:09:56 UTC XXX followers, XXX engagements
"7/12 Cash runway ✔ They ended Q1 2025 with $12.7M and raised another $5M in April. That covers pre-launch operations into early 2026 based on recent filings. No debt. Low burn. Theyre lean and laser-focused on launch" @dg_fit61882 on X 2025-07-23 19:33:27 UTC XXX followers, XXX engagements
"Bright Minds Biosciences $DRUG trades at $XXXXX giving it a market cap of $250M with just 7.08M shares outstanding (7375% institutional ownership) . Its lead molecule BMB101 is now in an open-label Phase X trial for absence epilepsy & DEE after XXX% seizure survival in SUDEP mouse models . TD Cowen and Chardan initiated Buy coverage with price targets in the $80$92 range . Highly selective 5HT2C agonist designed to minimize tolerance via Gq pathway activation. Phase X depends on upcoming data. #Biotech #Epilepsy #CNS #Microcap" @dg_fit61882 on X 2025-07-26 19:52:52 UTC XXX followers, XX engagements
"🚨 $CMG New position opened after earnings: CMG 10/17 XXXX C @ XXXX avg ✳ Q2 2025 Earnings Recap 🔹 Revenue: $3.06B (+3% YoY) 🔹 Same-store sales: X% (first decline since 2020) 🔹 EPS: $XXXX (in line) 🔹 Net income: $436M 🔹 Digital sales: XXXX% of total 🔹 Buybacks: $435.9M repurchased ($50/share); $838.8M still authorized ✳ Valuation (as of July XX 2025) 🔹 Market Cap: $62.7B 🔹 EV/EBITDA: XXXX 🔹 P/E (TTM): XX down XX% from 12mo avg (50) 🔹 Forward P/E: XX ✳ Outlook 🔹 FY25 guide: flat comp sales (cut from low-single digit growth) 🔹 Plan to open 315345 new units (80% with Chipotlanes) 🔹" @dg_fit61882 on X 2025-07-26 21:42:39 UTC XXX followers, XXX engagements
"🔬 Q3 2025 Phase X Readouts $LLY Donanemab (Alzheimers Disease) Eli Lillys anti-amyloid antibody is a front-runner in the Alzheimers race. Prior results showed cognitive slowing in early AD but safety concerns over ARIA remain under scrutiny. Q3 data could solidify approval odds. $ATAI GRX-055 (Intranasal 5-MeO-DMT for TRD). A fast-acting psychedelic analog designed for treatment-resistant depression. ATAI is testing whether a short psychedelic experience (via 5-MeO-DMT) can provide rapid symptom relief. A successful readout would validate a novel CNS delivery mechanism. $GBIO GB-501 (Gene" @dg_fit61882 on X 2025-07-27 21:42:29 UTC XXX followers, XXX engagements
"$PASG up XX% over that $X i was looking for. Took full position. See previous tweets" @dg_fit61882 on X 2025-07-25 13:36:47 UTC XXX followers, XXX engagements
"$VKTX just kicked off Phase X VANQUISH trials (VANQUISH1 & 2) for its GLP1/GIP dual agonist VK2735 with 6600 patients across 78-week arms testing doses of XXX XXXX & XXXX mg vs placebotargeting obese adults with/without T2D. Primary endpoint: % weight loss vs placebo at XX weeks . Meanwhile the VENTUREOral Phase X trial (280 patients) wrapped enrollment in Q1 and expects topline results in 2H 2025 featuring percent bodyweight change at XX weeks safety PK and dose response across multiple tablet doses . Why it matters: Strong oral data (8.2% mean loss in XX days) could validate VK2735 as an" @dg_fit61882 on X 2025-07-27 23:19:24 UTC XXX followers, XXX engagements
"$NVNI jumped nearly XX% at open after its NuviniAI day in So Paulo and unveiling its Latin American SaaS/AI strategy. They presented strong 2024 financials and outlined an M&A pipeline worth $127M targeting closing in Q3" @dg_fit61882 on X 2025-07-28 13:42:30 UTC XXX followers, XX engagements
"The biotech space is on fire. Which of these are you watching $SRPT $IXHL $ABVX $RPRX $CRSP $DNA Safety drama breakout charts big trials and buy signals Which ones on your radar and why Drop your take 👇 #Biotech #Stocks #Momentum" @dg_fit61882 on X 2025-07-26 14:42:40 UTC XXX followers, XXX engagements
"$SLRX surged over XXX% today after executing a 1-for-8 reverse stock split consolidating the cap and clearing Nasdaq bid-price issues. The company also received a fresh extensionuntil midAugustto regain compliance with the $2.5M equity standard. A third merger amendment with Decoy Therapeutics allows certain creditors to convert debt into Series B preferred stock. Legacy holders retain XXX% post-merger" @dg_fit61882 on X 2025-07-29 13:15:02 UTC XXX followers, XX engagements
"$PASG resistance @ XXX XXX XXXX XXX. Data soon" @dg_fit61882 on X 2025-07-25 15:14:20 UTC XXX followers, XX engagements
"$PASG just saw insider buying from XX% holder Lynx1 Capital128848 shares scooped in the $5.40$5.70 range ($720K). This lines up perfectly with the potential double bottom setup near $XXXX. Big money stepping in right where the chart needed it 👀 data soon" @dg_fit61882 on X 2025-07-25 02:04:45 UTC XXX followers, XXX engagements
"Adaptimmune $ADAP has agreed to sell its TECELRA letecel afamicel and uzacel Tcell therapy programs to US WorldMeds for $55M upfront + up to $30M in milestones closing this week. Post-close ADAP plans to reduce its workforce by XX% and exit leadership roles soon. The company will pivot to development of its PRAME- and CD70-directed programs. ##ADAP #CellTherapy #Biotech" @dg_fit61882 on X 2025-07-28 14:39:04 UTC XXX followers, XXX engagements
"$PASG Double Bottom If we pop with some volume ill take a position. Last reported cash 63mil. Market cap 16mil. Couple of catalysts this year. Anyone watching" @dg_fit61882 on X 2025-07-22 03:01:24 UTC XXX followers, XXX engagements
"@PeloSwing $LCID finally showing some life after months of tight range compression. This kind of move off the lows can catch shorts offside. Lets see if it can hold over $3" @dg_fit61882 on X 2025-07-26 18:16:06 UTC XXX followers, XXX engagements
"🚨 Big news: U.S. and EU strike a landmark trade deal U.S. to impose a XX% tariff on most EU goods in exchange for $XXX B in investments and $XXX B in energy & defense purchases from Europe Markets are rallying: all-time highs across $SPX $DJI $NDX and European equities like $SX5E (Euro Stoxx50) are gaining reducing downside risk and providing a welcome lift post-uncertainty. Investors view this as a stabilizing catalyst amid upcoming earnings and policy events. 💹 #trade #tariffs #marketrally" @dg_fit61882 on X 2025-07-27 18:50:17 UTC XXX followers, XX engagements
"8/ 🔭 Catalysts Still Coming Even in a tough tape 2H 2025 brings big moments: $PMN Phase 1b readout $IXHL Phase X data next week $ABVX launching Phase X UC $VYGR tau program advancing $ACAD mid-stage psychosis data Eyes on timelines" @dg_fit61882 on X 2025-07-27 02:12:59 UTC XXX followers, XXX engagements
"$PASG just took a starter. Will wait for volume to come in for a larger allocation" @dg_fit61882 on X 2025-07-22 14:53:58 UTC XXX followers, XXX engagements
"UnitedHealth $UNH July XX 2025 update: CEO shift in May: Stephen Hemsley returns after Andrew Witty steps down Q1 miss triggered withdrawal of 2025 forecast; guidance suspended DOJ has launched civil & criminal probes into MA billing practices Stock down 4045% in 2025; analysts maintain moderate buy consensus Forward P/E at 1415 roughly XX% below long-term average Outlook: focused on cost control in Medicare Advantage and turning Optum performance around Still massive scale & cash flow but visibility remains weak until Q2 numbers. #Healthcare #Insurance #UNH" @dg_fit61882 on X 2025-07-28 02:10:12 UTC XXX followers, XXX engagements
"@PeloSwing Bought some long term $CMG XXXX calls" @dg_fit61882 on X 2025-07-26 21:02:14 UTC XXX followers, XX engagements
"9/ 🧵 XX Stocks to Watch Across the Sector Heres a mix of leaders innovators and speculative names: $LLY $RHHBY $CRSP $EDIT $BEAM $VYGR $ACAD $PMN $ABVX $IXHL $REGN $BIIB $MGNX $CELA $NVAX $SPRO $XOMA $GNFT $VRTX $ICON Tag your favorites" @dg_fit61882 on X 2025-07-27 02:13:00 UTC XXX followers, XXX engagements
"$PASG 3x average volume up 8%. Will look for continuation over $X for a full entry" @dg_fit61882 on X 2025-07-22 20:01:17 UTC XXX followers, XX engagements
"$DMAC is on deck for a pivotal readout: preliminary safety BP & placental flow data from Phase X Part 1A preeclampsia study are expected midJuly. With no approved treatments and $37M cash to Q3 2026 this could mark a breakthroughor highlight early safety/efficacy risks" @dg_fit61882 on X 2025-07-13 19:00:10 UTC XXX followers, XXX engagements
"🚨 U.S. and EU strike a landmark trade deal U.S. to impose a XX% tariff on most EU goods in exchange for $XXX B in investments and $XXX B in energy & defense purchases from Europe Markets are rallying: all-time highs across $SPX $DJI $NDX and European equities like $SX5E (Euro Stoxx50) are gaining reducing downside risk and providing a welcome lift post-uncertainty. Investors view this as a stabilizing catalyst amid upcoming earnings and policy events. 💹 #trade #tariffs #marketrally" @dg_fit61882 on X 2025-07-27 19:28:42 UTC XXX followers, XXX engagements